Edition:
United States

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

3.20USD
12:25pm EDT
Change (% chg)

$-0.10 (-3.03%)
Prev Close
$3.30
Open
$3.35
Day's High
$3.35
Day's Low
$3.20
Volume
9,234
Avg. Vol
26,969
52-wk High
$6.45
52-wk Low
$2.05

Chart for

About

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02... (more)

Overall

Beta: --
Market Cap(Mil.): $86.63
Shares Outstanding(Mil.): 26.25
Dividend: --
Yield (%): --

Financials

  AXSM.OQ Industry Sector
P/E (TTM): -- 103.50 32.14
EPS (TTM): -1.09 -- --
ROI: -125.26 1.52 12.66
ROE: -181.10 0.25 14.84

BRIEF-Axsome Therapeutics Reports Q1 Loss Per Share Of $0.19

* AXSOME THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 08 2018

BRIEF-Axsome Therapeutics Announces First Patient Enrolled In Phase 2 Clinical Trial Of AXS-05 In Smoking Cessation

* AXSOME THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF AXS-05 IN SMOKING CESSATION Source text for Eikon: Further company coverage:

Apr 23 2018

BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer

* AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER

Apr 19 2018

Earnings vs. Estimates